|
1
|
Imai A, Furui T and Yamamoto A:
Preservation of female fertility during cancer treatment. Reprod
Med Biol. 7:17–27. 2008. View Article : Google Scholar
|
|
2
|
Yap JK and Davies M: Fertility
preservation in female cancer survivors. J Obstet Gynaecol.
27:390–400. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maltaris T, Seufert R, Fischl F,
Schaffrath M, Pollow K, Koelbl H and Dittrich R: The effect of
cancer treatment on female fertility and strategies for preserving
fertility. Eur J Obstet Gynecol Reprod Biol. 130:148–155. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pham E, Yin M, Peters CG, Lee CR, Brown D,
Xu P, Man S, Jayaraman L, Rohde E, Chow A, et al: Preclinical
efficacy of bevacizumab with CRLX101, an investigational
nanoparticle-drug conjugate, in treatment of metastatic
triple-negative breast cancer. Cancer Res. 76:4493–4503. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schneeweiss A, Förster F, Tesch H, Aktas
B, Gluz O, Geberth M, Hertz-Eichenrode MM, Schönegg W, Schumacher
C, Kutscheidt A, et al: First-line bevacizumab-containing therapy
for HER2-negative metastatic breast cancer: final results from a
prospective german study. Anticancer Res. 36:967–974.
2016.PubMed/NCBI
|
|
6
|
McClung EC and Wenham RM: Profile of
bevacizumab in the treatment of platinum-resistant ovarian cancer:
current perspectives. Int J Womens Health. 8:59–75. 2016.PubMed/NCBI
|
|
7
|
Marchetti C, de Felice F, Palaia I,
Musella A, Di Donato V, Gasparri ML, Musio D, Muzii L, Tombolini V
and Panici PB: Efficacy and toxicity of bevacizumab in recurrent
ovarian disease: an update meta-analysis on phase III trials.
Oncotarget. 7:13221–13227. 2016.PubMed/NCBI
|
|
8
|
Stratigos M, Matikas A, Voutsina A,
Mavroudis D and Georgoulias V: Targeting angiogenesis in small cell
lung cancer. Transl Lung Cancer Res. 5:389–400. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stinchcombe TE: Targeted therapies for
lung cancer. Cancer Treat Res. 170:165–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saltz LB: Bevacizumab in colorectal
cancer: it should have worked. Lancet Oncol. 17:1469–1470. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ilic I, Jankovic S and Ilic M: Bevacizumab
combined with chemotherapy improves survival for patients with
metastatic colorectal cancer: evidence from meta analysis. PLoS
One. 11:e01619122016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bizzarri N, Ghirardi V, Alessandri F,
Venturini PL, Menada M Valenzano, Rundle S, Maggiore U Leone
Roberti and Ferrero S: Bevacizumab for the treatment of cervical
cancer. Expert Opin Biol Ther. 16:407–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oaknin A, Rubio MJ, Redondo A, de Juan A,
Bañuelos JF Cueva, Gil-Martin M, Ortega E, Garcia-Arias A,
Gonzalez-Martin A and Bover I: SEOM guidelines for cervical cancer.
Clin Transl Oncol. 17:1036–1042. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stone RL, Sood AK and Coleman RL:
Collateral damage: toxic effects of targeted antiangiogenic
therapies in ovarian cancer. Lancet Oncol. 11:465–475. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dunlop CE and Anderson RA: The regulation
and assessment of follicular growth. Scand J Clin Lab Invest Suppl.
244:13–17, discussion 17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsueh AJ, Kawamura K, Cheng Y and Fauser
BC: Intraovarian control of early folliculogenesis. Endocr Rev.
36:1–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Araújo VR, Duarte AB, Bruno JB, Lopes CA
Pinho and de Figueiredo JR: Importance of vascular endothelial
growth factor (VEGF) in ovarian physiology of mammals. Zygote.
21:295–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Byrne AM, Bouchier-Hayes DJ and Harmey JH:
Angiogenic and cell survival functions of vascular endothelial
growth factor (VEGF). J Cell Mol Med. 9:777–794. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dvorak HF: VPF/VEGF and the angiogenic
response. Semin Perinatol. 24:75–78. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Emori C and Sugiura K: Role of
oocyte-derived paracrine factors in follicular development. Anim
Sci J. 85:627–633. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Field SL, Dasgupta T, Cummings M and Orsi
NM: Cytokines in ovarian folliculogenesis, oocyte maturation and
luteinisation. Mol Reprod Dev. 81:284–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hennet ML and Combelles CM: The antral
follicle: a microenvironment for oocyte differentiation. Int J Dev
Biol. 56:819–831. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Familiari G, Caggiati A, Nottola SA,
Ermini M, Di Benedetto MR and Motta PM: Ultrastructure of human
ovarian primordial follicles after combination chemotherapy for
Hodgkins disease. Hum Reprod. 8:2080–2087. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stouffer RL, Martínez-Chequer JC,
Molskness TA, Xu F and Hazzard TM: Regulation and action of
angiogenic factors in the primate ovary. Arch Med Res. 32:567–575.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tamanini C and De Ambrogi M: Angiogenesis
in developing follicle and corpus luteum. Reprod Domest Anim.
39:206–216. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barboni B, Turriani M, Galeati G, Spinaci
M, Bacci ML, Forni M and Mattioli M: Vascular endothelial growth
factor production in growing pig antral follicles. Biol Reprod.
63:858–864. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Greenaway J, Connor K, Pedersen HG,
Coomber BL, LaMarre J and Petrik J: Vascular endothelial growth
factor and its receptor, Flk-1/KDR, are cytoprotective in the
extravascular compartment of the ovarian follicle. Endocrinology.
145:2896–2905. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Celik-Ozenci C, Akkoyunlu G, Kayisli UA,
Arici A and Demir R: Localization of vascular endothelial growth
factor in the zona pellucida of developing ovarian follicles in the
rat: a possible role in destiny of follicles. Histochem Cell Biol.
120:383–390. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Harata T, Ando H, Iwase A, Nagasaka T,
Mizutani S and Kikkawa F: Localization of angiotensin II, the AT1
receptor, angiotensin-converting enzyme, aminopeptidase A,
adipocyte-derived leucine aminopeptidase, and vascular endothelial
growth factor in the human ovary throughout the menstrual cycle.
Fertil Steril. 86:433–439. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Otani N, Minami S, Yamoto M, Shikone T,
Otani H, Nishiyama R, Otani T and Nakano R: The vascular
endothelial growth factor/fms-like tyrosine kinase system in human
ovary during the menstrual cycle and early pregnancy. J Clin
Endocrinol Metab. 84:3845–3851. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Geva E and Jaffe RB: Role of vascular
endothelial growth factor in ovarian physiology and pathology.
Fertil Steril. 74:429–438. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Geva E and Jaffe RB: Role of angiopoietins
in reproductive tract angiogenesis. Obstet Gynecol Surv.
55:511–519. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wulff C, Wilson H, Wiegand SJ, Rudge JS
and Fraser HM: Prevention of thecal angiogenesis, antral follicular
growth, and ovulation in the primate by treatment with vascular
endothelial growth factor Trap R1R2. Endocrinology. 143:2797–2807.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zimmermann RC, Hartman T, Kavic S, Pauli
SA, Bohlen P, Sauer MV and Kitajewski J: Vascular endothelial
growth factor receptor 2-mediated angiogenesis is essential for
gonadotropin-dependent follicle development. J Clin Invest.
112:659–669. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hazzard TM, Xu F and Stouffer RL:
Injection of soluble vascular endothelial growth factor receptor 1
into the preovulatory follicle disrupts ovulation and subsequent
luteal function in rhesus monkeys. Biol Reprod. 67:1305–1312. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Heath JA and Stern CJ: Fertility
preservation in children newly diagnosed with cancer: existing
standards of practice in Australia and New Zealand. Med J Aust.
185:538–541. 2006.PubMed/NCBI
|
|
37
|
Lee SJ, Schover LR, Partridge AH, Patrizio
P, Wallace WH, Hagerty K, Beck LN, Brennan LV and Oktay K: American
Society of Clinical Oncology: American Society of Clinical Oncology
recommendations on fertility preservation in cancer patients. J
Clin Oncol. 24:2917–2931. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Meirow D: Ovarian injury and modern
options to preserve fertility in female cancer patients treated
with high dose radio-chemotherapy for hemato-oncological neoplasias
and other cancers. Leuk Lymphoma. 33:65–76. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Meirow D, Levron J, Eldar-Geva T, Hardan
I, Fridman E, Zalel Y, Schiff E and Dor J: Pregnancy after
transplantation of cryopreserved ovarian tissue in a patient with
ovarian failure after chemotherapy. N Engl J Med. 353:318–321.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schimmer AD, Quatermain M, Imrie K, Ali V,
McCrae J, Stewart AK, Crump M, Derzko C and Keating A: Ovarian
function after autologous bone marrow transplantation. J Clin
Oncol. 16:2359–2363. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Blumenfeld Z: Ovarian rescue/protection
from chemotherapeutic agents. J Soc Gynecol Investig. 8 Suppl
Proceedings:60–64. 2001. View Article : Google Scholar
|
|
42
|
Blumenfeld Z: Preservation of fertility
and ovarian function and minimalization of chemotherapy associated
gonadotoxicity and premature ovarian failure: the role of inhibin-A
and -B as markers. Mol Cell Endocrinol. 187:93–105. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Blumenfeld Z, Dann E, Avivi I, Epelbaum R
and Rowe JM: Fertility after treatment for Hodgkins disease. Ann
Oncol. 13 Suppl 1:138–147. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Blumenfeld Z, Shapiro D, Shteinberg M,
Avivi I and Nahir M: Preservation of fertility and ovarian function
and minimizing gonadotoxicity in young women with systemic lupus
erythematosus treated by chemotherapy. Lupus. 9:401–405. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Brydøy M, Fosså SD, Dahl O and Bjøro T:
Gonadal dysfunction and fertility problems in cancer survivors.
Acta Oncol. 46:480–489. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Larsen EC, Müller J, Schmiegelow K,
Rechnitzer C and Andersen AN: Reduced ovarian function in long-term
survivors of radiation- and chemotherapy-treated childhood cancer.
J Clin Endocrinol Metab. 88:5307–5314. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Syrigos KN, Karapanagiotou E, Boura P,
Manegold C and Harrington K: Bevacizumab-induced hypertension:
pathogenesis and management. BioDrugs. 25:159–169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Corr BR, Breed C, Sheeder J, Weisdack S
and Behbakht K: Bevacizumab induced hypertension in gynecologic
cancer: does it resolve after completion of therapy? Gynecol Oncol
Rep. 17:65–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sarno MA, Mancari R, Colombo HA Jr, Azim N
and Peccatori FA: Are monoclonal antibodies a safe treatment for
cancer during pregnancy? Immunotherapy. 5:733–741. 2013. View Article : Google Scholar : PubMed/NCBI
|
